Artrya lands largest U.S. customer as SAPPHIRE strategy delivers first commercial conversion
Artrya Limited (ASX: AYA) has signed a five-year commercial agreement with Huntsville Hospital Health System (HH Health), marking the first conversion of a SAPPHIRE Study participant into a paying commercial customer. The agreement makes HH Health Artrya’s fourth U.S. commercial customer and its largest U.S. deployment to date, with Salix® set to be integrated into applicable clinical workflows across HH Health’s 15-hospital network.
The agreement carries a minimum contracted value of US$0.5M for Salix® Coronary Anatomy, with additional fee-per-scan revenue available from the Salix® Coronary Plaque and Salix® Coronary Flow modules, the latter subject to FDA clearance.
When big ASX news breaks, our subscribers know first
What the HH Health agreement means in practice
The HH Health deal establishes a three-tier revenue structure within a single commercial relationship, giving Artrya both recurring and usage-based income streams from one customer.
The US$0.5M minimum contracted value applies exclusively to Salix® Coronary Anatomy and does not capture potential upside from the Plaque and Flow modules. Material terms of the agreement include:
- Agreement type: Commercial SaaS Licence Agreement for non-exclusive clinical use of Salix® Coronary Anatomy
- Subscription: Monthly subscription fee over the 5-year term for Salix® Coronary Anatomy
- Fee-per-scan (Plaque): Salix® Coronary Plaque, eligible for U.S. reimbursement under a Category I CPT code
- Fee-per-scan (Flow): Salix® Coronary Flow, eligible for U.S. reimbursement under a Category I CPT code once FDA cleared
- Term: 5 years, with standard provisions for events of default and customary termination provisions
- Customary terms: Security and privacy protocols, support levels, and software upgrades
Understanding SAPPHIRE — and why this conversion matters
SAPPHIRE is a clinical study network that forms part of Artrya’s broader U.S. clinical and commercial strategy. The programme establishes collaborations with leading, high-volume cardiovascular centres in the United States, giving participating organisations direct hands-on exposure to the Salix® platform during clinical research activities.
The SAPPHIRE Study network was built on the principle that high-volume cardiovascular centres would gain direct clinical exposure to Salix before any commercial decision was required, with participating institutions like Dignity Health Arizona joining to generate real-world evidence across diverse patient populations.
For investors, the strategic logic is straightforward: SAPPHIRE is not simply a research programme. It is designed to function as a structured pipeline for commercial customer conversion. By embedding Salix® within the clinical workflows of major cardiovascular centres, Artrya aims to build the institutional familiarity and clinical confidence that leads to long-term commercial adoption.
HH Health is the first SAPPHIRE participant to complete that journey, progressing from a research collaboration into a five-year commercial agreement for routine clinical use. Artrya noted it will continue to progress its relationships with other SAPPHIRE participants alongside its broader U.S. commercial activities.
John Konstantopoulos, Co-Founder and CEO
“The conversion of HH Health from a SAPPHIRE Study participant into a commercial customer is an important milestone for Artrya’s U.S. strategy… Huntsville becoming the first SAPPHIRE participant to enter into a five-year commercial agreement demonstrates that strategy in action.”
Four U.S. commercial customers and a clear growth path ahead
With HH Health now signed, Artrya has four U.S. commercial customers across its Salix® platform. HH Health represents the largest deployment by network scale to date, spanning 15 hospitals within the broader health system.
| Customer | Agreement Type | Key Detail | SAPPHIRE Origin | Status |
|---|---|---|---|---|
| Tanner Health | Commercial | — | No | Active |
| Northeast Georgia Health System | Commercial | — | No | Active |
| Cone Health | Commercial | — | No | Active |
| Huntsville Hospital Health System | 5-Year Commercial SaaS Licence Agreement | 15-hospital network / US$0.5M minimum contracted value (Salix® Coronary Anatomy) | Yes (first conversion) | Signed October 2026 |
Agreement details for Tanner Health, Northeast Georgia Health System, and Cone Health are not disclosed in this announcement.
Artrya’s stated focus is on successfully deploying Salix® across all four commercial customers while continuing to progress SAPPHIRE relationships and broader U.S. commercial activities. The source announcement does not quantify the forward pipeline of additional SAPPHIRE conversions or new commercial prospects.
Shareholders will have the opportunity to hear directly from management at an Investor Webinar hosted by Co-Founder and CEO John Konstantopoulos on Wednesday, 7 October 2026, at 12.00pm AEDT / 9.00am AWST, including a Q&A session. A recording will be made available on the company’s Investor Centre for 60 days following the call.
For investors exploring the financial foundations behind this commercial momentum, our full explainer on Artrya’s FY26 financial results covers the $74 million cash position, the revenue accounting treatment across foundation partners, and the FDA clearance timeline for Salix Coronary Flow that would unlock the highest-value module across all contracted sites.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who never miss a market-moving moment. Click the “Free Alerts” button at StockWire X to get started today.